Seres Therapeutics (MCRB) Misses Q3 EPS by 6c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.38), $0.06 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Morgan Stanley Upgrades Sangfor Technologies Inc (300454:CH) to Overweight